UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
PD-1 inhibitors have revolutionised cancer treatment over the last decade, with their success attributed to Keytruda and ...
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...
A new approach to cancer treatment became available shortly before Jimmy Carter needed it. Now it's a pillar of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback